Evaluating Initial Empiric Therapy for Neutropenic Fever in Vancomycin-Resistant Enterococcus-Colonized Patients

Area of Science:

• Infectious Diseases
• Oncology
• Pharmacology

Background:

• Vancomycin-resistant enterococcus (VRE) infections pose a significant mortality risk in oncology patients.
• The low incidence of VRE bacteremia and advancements in rapid diagnostics challenge the necessity of empiric VRE-directed therapy.
• Empiric VRE-directed therapy may increase antimicrobial resistance, drug toxicity, and healthcare costs.

Purpose of the Study:

• To evaluate the clinical necessity and impact of empiric vancomycin-resistant enterococcus (VRE)-directed antimicrobial therapy in VRE-colonized oncology patients with neutropenic fever.
• To assess the association between empiric VRE-directed therapy and outcomes such as mortality, VRE bacteremia incidence, and healthcare costs.

Main Methods:

• A retrospective study stratified VRE-colonized adult patients undergoing hematopoietic stem cell transplantation or induction therapy for acute leukemia/myeloid sarcoma with neutropenic fever.
• Patients were categorized based on the development of VRE bacteremia and whether they received empiric VRE-directed therapy (Empiric Therapy vs. non-Empiric Therapy) for their first neutropenic fever episode.
• Primary endpoints included VRE-related, in-hospital, and 100-day mortality rates. Secondary outcomes encompassed VRE bacteremia incidence, length of stay, Clostridioides difficile infection rates, and therapy duration and cost.

Main Results:

• Only 4% of eligible patients developed VRE bacteremia during their first neutropenic fever episode; none of these patients died.
• Patients receiving Empiric Therapy had significantly longer duration and higher costs associated with VRE-directed therapy compared to the non-Empiric Therapy group.
• No significant differences in clinical outcomes were observed between the Empiric Therapy and non-Empiric Therapy groups.

Conclusions:

• Empiric vancomycin-resistant enterococcus (VRE)-directed therapy offers no discernible clinical benefit for VRE-colonized oncology patients with neutropenic fever.
• This approach exposes a majority of patients to unnecessary treatment, increasing drug toxicities and institutional costs.
• Delaying VRE-directed therapy until organism identification does not appear to impact mortality, supporting the consideration of omitting empiric VRE treatment.